FIA
ATXS

FNY Investment Advisers’s Astria Therapeutics ATXS Stock Holding History

FNY Investment Advisers’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-33
Closed -$1K – 811
2019
Q3 		$1K Hold
33
– – ﹤0.01% 791
2019
Q2 		$1K Hold
33
– – ﹤0.01% 876
2019
Q1 		$1K Hold
33
– – ﹤0.01% 639
2018
Q4 		$0 Hold
33
– – ﹤0.01% 681
2018
Q3 		$1K Buy
+33
New +$1.48K ﹤0.01% 768

Other funds holding ATXS

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

FNY Investment Advisers's ATXS Position: Q4 2019 in Review

FNY Investment Advisers sold out of Astria Therapeutics (ATXS) in Q4 2019, closing a stake of 33 shares — an estimated $1K sold.

FNY Investment Advisers first reported a position in ATXS in Q3 2018 and held it in 5 quarters. The position peaked at $1K in Q3 2019. 28 funds tracked by Wall St. Rank hold ATXS as of Q4 2019.

  • FNY Investment Advisers reported no remaining Astria Therapeutics position as of Q4 2019 after selling out during the quarter.
  • FNY Investment Advisers sold 33 Astria Therapeutics shares in Q4 2019, an estimated $1K.
  • FNY Investment Advisers first reported a position in Astria Therapeutics in Q3 2018 and held it in 5 quarters.
  • FNY Investment Advisers's Astria Therapeutics position peaked at $1K in Q3 2019.
  • 28 funds tracked by Wall St. Rank held Astria Therapeutics as of Q4 2019.

Based on FNY Investment Advisers's 13F filing for Q4 2019, filed 10 Jan 2020.